Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.33
$0.25
$1.20
$17.03M1.19170,955 shs4.12 million shs
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$14.72
-1.9%
$17.69
$4.66
$34.05
$57.53M1.66134,027 shs1.47 million shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.88
$4.75
$0.53
$5.25
$49.13M-1.689,599 shs11,801 shs
ProKidney Corp. stock logo
PROK
ProKidney
$0.66
-5.2%
$0.81
$0.46
$2.61
$203.80M1.35634,934 shs1.80 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-32.71%-69.91%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.00%-4.28%+8.54%-1.70%+23.15%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%-1.21%0.00%+82.77%+92.89%
ProKidney Corp. stock logo
PROK
ProKidney
-5.20%-21.26%-14.41%-31.25%-75.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
1.6816 of 5 stars
3.20.00.00.00.64.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
2.33
Hold$4.50581.71% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$4.46M12.90N/AN/A$6.78 per share2.17
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M18.38N/AN/A($11.55) per share-0.42
ProKidney Corp. stock logo
PROK
ProKidney
$80K2,415.14N/AN/A($3.41) per share-0.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)

Latest MGEN, OPGN, ENZ, and PROK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.13+$0.03-$0.13N/A$0.23 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.20
4.23
4.23
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
ProKidney Corp. stock logo
PROK
ProKidney
N/A
10.96
10.96

Institutional Ownership

CompanyInstitutional Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/A
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%

Insider Ownership

CompanyInsider Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
1.10%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
ProKidney Corp. stock logo
PROK
ProKidney
41.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
453.91 millionN/ANot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
ProKidney Corp. stock logo
PROK
ProKidney
3292.70 million171.26 millionOptionable

Recent News About These Companies

Another Big Office Landlord Tests Sales Climate
ProKidney Corp.
ProKidney reports FY24 EPS (62c), consensus (59c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Miragen Therapeutics stock logo

Miragen Therapeutics NASDAQ:MGEN

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.88 0.00 (0.00%)
As of 06/20/2025 03:51 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

ProKidney stock logo

ProKidney NASDAQ:PROK

$0.66 -0.04 (-5.20%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$0.73 +0.07 (+10.59%)
As of 06/20/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.